SCHEMBL5402034

SCHEMBL5402034

C=CCc1ccccc1OCc1nnc(NS(=O)(=O)c2cccc(Cl)c2C)s1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.41
HSD11B1 P28845 6/20 0.41
HSD17B1 P14061 2/20 0.40
HSD17B2 P37059 2/20 0.40
RECQL P46063 1/20 0.39
CCR4 P51679 1/20 0.38
SLC40A1 Q9NP59 1/20 0.38
SCN1A P35498 1/20 0.38
SCN5A Q14524 1/20 0.38
SCN8A Q9UQD0 1/20 0.38
EDNRB P24530 1/20 0.37
EDNRA P25101 1/20 0.37
MEN1 O00255 1/20 0.37
MAPT P10636 1/20 0.37
PKM P14618 1/20 0.37
HPGD P15428 1/20 0.37
APEX1 P27695 1/20 0.37
PTPN7 P35236 1/20 0.37
BLM P54132 1/20 0.37
KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5401332 0.84 MAPT (0.49) ALDH1A1HSD11B1HSD17B1HSD17B2RECQL
SCHEMBL5396556 0.79 MEN1 (0.47) ALDH1A1HSD11B1HSD17B1HSD17B2RECQL
SCHEMBL5398285 0.79 NPC1 (0.54) ALDH1A1HSD11B1RECQLMEN1MAPT
SCHEMBL5397908 0.76 ATM (0.59) HSD11B1HSD17B1HSD17B2CCR4EDNRB
SCHEMBL5389541 0.75 ALDH1A1 (0.56) ALDH1A1HSD11B1RECQLMEN1MAPT
SCHEMBL5831102 0.74 HSD11B1 (0.49) ALDH1A1HSD11B1HSD17B1HSD17B2CCR4
SCHEMBL5831177 0.74 HSD11B1 (0.51) ALDH1A1HSD11B1HSD17B1HSD17B2SLC40A1
SCHEMBL5831865 0.74 ALDH1A1 (0.47) ALDH1A1HSD11B1HSD17B1HSD17B2RECQL
SCHEMBL5831070 0.73 HSD11B1 (0.48) ALDH1A1HSD11B1HSD17B1HSD17B2CCR4
SCHEMBL5410267 0.73 MAPT (0.48) ALDH1A1HSD11B1HSD17B1HSD17B2EDNRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070066614-A1 Ihibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB 2007-03-22 US claimed
US-7173030-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2007-02-06 US claimed
EP-1631558-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE I BIOVITRUM AB (SE) 2006-03-08 EP claimed
US-20050009821-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB 2005-01-13 US claimed
WO-2004103980-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE I BIOVITRUM AB (SE) 2004-12-02 WO claimed
US-20070066614-A1 Ihibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB 2007-03-22 US disclosed
US-7173030-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2007-02-06 US disclosed
EP-1631558-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE I BIOVITRUM AB (SE) 2006-03-08 EP disclosed
US-20050009821-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB 2005-01-13 US disclosed
WO-2004103980-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE I BIOVITRUM AB (SE) 2004-12-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009821-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD11B2 ALDH1A1 53/4885HSD11B1 1/4885HSD17B1 2/4885
US-20070066614-A1 Ihibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD17B11 ALDH1A1 36/4885HSD11B1 1/4885HSD17B1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.